DOCSLIB.ORG

Understanding Pyoderma Gangrenosum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Understanding Pyoderma Gangrenosum PRACTICE DEVELOPMENT Understanding pyoderma gangrenosum KEY WORDS Pyoderma gangrenosum (PG) is a rare immune-related chronic ulcerating skin Immunosuppression condition with a predilection for the lower limbs. It is more common in females, Pathergy with the average age of onset between 20 and 50 years. There are two stages of the Pyoderma gangrenosum disease process: an ulcerative phase and a healing phase. The latter occurs once the heightened and ongoing inflammatory response has subsided, although the exact pathophysiology of PG has yet to be elucidated. Half of the cases of PG are associated with other comorbidities, such as inflammatory bowel disease, arthritis or haematological malignancies. The skin condition pathergy can be a stimulus for the onset of the disease and is due to incidental or healthcare-related trauma. There is no definitive test to diagnose PG and the diagnosis is one of exclusion. The aim of the treatment is to reduce the inflammation and therefore immunosuppression is the basis of any therapy. Nevertheless, the disease can recur following completion of the healing phase. G is a chronic ulcerating skin condition INCIDENCE OF PG that appears to be immune-mediated. It Patel et al (2015) report incidence of PG as is characterised by deep skin ulcers with 3–10 patients per million worldwide. In Europe, Pundermined edges that occur most often on incidence is thought to be six million per year, with the lower limbs but may affect any skin surface children accounting for 4% of that number (Teagle (Brooklyn et al, 2006a). and Hargest, 2014). It is an overactive inflammatory response to There is a reported female predominance for traumatic, inflammatory or neoplastic process PG (Laun et al, 2016; Sasor et al, 2018) and the and is therefore classified as a systemic auto- condition is most common among 20–50 year olds inflammatory disease (Ratnagobal and Sinha, 2013; (Adusen et al, 2016). There is significant morbidity Adışen et al, 2016). due to pain and poor wound healing, and the mortality rate is three times higher in people with HISTORY PG than the general population — higher still when Brocq, a French dermatologist, first described PG in the patient also has inflammatory bowel disease 1908 as Phagedenisme Geometrique (Gameiro et (IBD) (Mehrtens and Crawley, 2015). al, 2015). In 1931 Brunsting renamed it Pyoderma gangrenosum, believing it to be a disseminated PATHOPHYSIOLOGY streptococcal infection causing cutaneous gangrene In the general population, there is a self-limiting (Teagle and Hargest, 2014). In the 1930s, patients inflammatory response, however, patients with with Rheumatoid Arthritis were treated with PG have a heightened and ongoing inflammatory cortisone and it was noted their co-existent PG response. The duration of this abnormal TRUDIE YOUNG ulcers started to heal: the theory of PG migrated inflammatory response may last weeks to many Director of Education and Training, from infective to autoimmune (Mehrtens and years (Ratnagobal and Sinha, 2013). There are two Welsh Wound Innovation Centre, Ynysmaerdy, Rhondda Cynon Taff, Crawley, 2015). The bullous variant of PG was first stages of the disease: the active, ulcerative stage and Wales described in 1972 (Ratnsglobal and Sinha, 2013). the wound healing stage (Gameiro et al, 2015). Wounds UK | Vol 14 | No 5 | 2018 87 PRACTICE DEVELOPMENT Unfortunately, the cause and exact pathophysiology The individual will present with pain that is Box 1. Proposed diagnostic criteria (Su et al, 2004) of PG is not well understood. However, there is often thought to be out of proportion to the size of the ulcer bed (Schotanus et al, 2014; Tay et al, Major criteria: thought to be an abnormal functioning of the neutrophils (Teagle and Hargest, 2014; Patel et al 2014) and should be screened for the underlying • a painful rapidly progressing 2015; Abtahi-naeini et al, 2016; Laun et al, 2016), associated diseases (Ratnagobal and Sinha, 2013). ulcer which is affected by alterations in chemotaxis and In 2004, Su et al proposed a framework to aid • exclusion of other causes of ulceration phagocytosis (Ratnaglobal and Sinah, 2013). the diagnosis of PG (Box 1). A positive diagnosis is Genetic factors and mutations have been made if the individual has two major and at least Minor criteria: identified in patients with PG, as demonstrated two minor diagnostic characteristics. • the presence of systemic diseases in PAPA syndrome (pyogenic arthritis, PG, acne) As is evident in Box 2, PG is often confused with associated with PG • history suggestive of pathergy and PASH syndrome (PG, acne, suppurative other skin conditions/diseases (Sasor et al, 2018). • characteristic histopathological hidradenitis) (Mehrtens and Crawley, 2015; Furthermore, inability to distinguish between sub- findings Braswell et al, 2015; Shavit et al, 2017). types of PG can delay diagnosis and have serious • response to systemic steroids or clinical consequences (Brooklyn et al, 2006a), immunosuppression ONSET including delayed treatment and negative effects The onset of PG is variable: some patients present on quality of life. with one or two slowly growing ulcers, others Box 2. Differential diagnosis experience the sudden appearance of multiple PATHERGY • Skin infection, skin malignancy, rapidly enlarging ulcers (Patel et al, 2015). In a Pathergy is defined as a pathological hyper- vascular ulceration, systemic retrospective study of 27 patients, the disease reactivity to normal stimuli (Teagle and Hargest, conditions — systemic lupus duration spanned between 15 and 14,600 days 2014). In PG, 25% of cases are triggered by erythematosus, rheumatoid (Adisen et al, 2016). pathergy due to incidental or healthcare-related arthritis, Behcet's disease, Around 50% of cases of PG are associated with trauma (Ormerod et al, 2015). Examples of Wegener's granulomatosis, and another underlying condition, the remaining 50% pathergy-induced PG include wound infection and Sweet's syndrome (Brooklyn et are idiopathic, having no known cause (Teagle and surgical procedures, e.g. caesarean section, breast al, 2006) • Drug reaction, insect bite, Hargest, 2014). reduction and central line insertion (Braswell et factitious disorder, dermatitis PG can also occur in patients with HIV, solid al, 2015; Patel et al, 2015, Abtahi-naeini et al, 2016, artefacta (Teagle and Hargest, tumours and during pregnancy (Gameiro et al, Pichler et al, 2016). Stoma formation can induce 2014; Schotanus et al, 2014; 2015; Shavit et al, 2017) and can be drug-induced, PG along with accompanying excoriation from Montero et al, 2016). with Isotretinoin reported as a causative agent bowel contents and skin stripping during removal • Necrotising fasciitis as can occur (Teagle and Hargest, 2014). of containment device (Wallace, 2017). in the vulva, groin and penis (Tay Litvinov and Sasseville (2014) report a case of et al, 2014; Bhaskaran et al, 2016). DIAGNOSIS PG hastened by red tattoo dye, which caused an • Allergic contact dermatitis in In the absence of a definitive test (serologic or allergic contact dermatitis — the pathergy trigger. peristomal PG (Afifi et al, 20180) histological), PG is diagnosed by exclusion of other diseases (Patel et al, 2015; Wallace, 2017). TYPES OF PG Nevertheless, a biopsy will be taken from the There are five subtypes of PG and an individual ulcer bed and the adjacent skin and sent for can suffer from more than one subtype at any one histological examination (Patel et al, 2015). A time (Gameiro et al, 2015) (Box 3). typical biopsy result will identify a neutrophil and Classic PG is associated with IBD, arthritis other inflammatory cell infiltration into the dermis and haematological malignancies, with 25–50% (Brooklyn et al, 2006b; Schotanus et al, 2014, associated with pathergy (Brooklyn et al, 2006b; Teagle and Hargest, 2014). If the PG inflammation Teagle and Hargest, 2014). is minimal, the biopsy result will identify non- The clinical presentation is of a deep ulcer specific histopathology (Shavit et al, 2017). that can extend into the subcutaneous fat In PG, the generic systemic inflammatory and fascia, with a purulent or haemorrhagic markers will be raised, e.g. C-reactive protein, and discharge (Schotanus et al, 2014). The ulcer has more so in the active ulcerative stage of the disease a well-defined undermined violaceous border (Tay et al, 2014). accompanied by erythema of the surrounding 88 Wounds UK | Vol 14 | No 5 | 2018 PRACTICE DEVELOPMENT Box 3. Five subtypes of pyoderma gangrenosum • Classic pyoderma gangrenosum • Peristomal pyoderma gangrenosum • Pustular pyoderma gangrenosum • Bullous pyoderma gangrenosum • Vegitative/superficial pyoderma gangrenosum Figure 1. Classic PG Figure 2. Healed PG skin (Figure 1). It often starts as a small papule or The clinical presentation is rapidly evolving collection of papules that break down to form painful concentric bullae and vesicles that spread small ulcers that coalesce and form a wound with swiftly in a concentric pattern with a violaceous a necrotic centre. The individual is systematically flare that can develop into superficial ulcers unwell with symptoms such as fever, malaise, (Ratnaglobal and Sinha, 2013; Schotanus et al, arthralgia and myalgia. The ulcers, commonly 2014). found on the legs, are excruciatingly painful and It affects the upper limbs and face and dorsum of form unsightly, cribriform scarring. the hands (Shavit et al, 2017). Peristomal PG is associated with IBD and Vegetative/superficial granulomatous PG occurs close to abdominal stomas,
Load more

Recommended publications
  • Pyoderma Gangrenosum and Cobalamin
    Teoh et al. BMC Rheumatology (2021) 5:7 https://doi.org/10.1186/s41927-021-00177-4 BMC Rheumatology CASE REPORT Open Access Pyoderma gangrenosum and cobalamin deficiency in systemic lupus erythematosus: a rare but non fortuitous association Sing Chiek Teoh1, Chun Yang Sim2* , Seow Lin Chuah3, Victoria Kok1 and Cheng Lay Teh3 Abstract Background: Pyoderma gangrenosum (PG) is an uncommon, idiopathic, ulcerative neutrophilic dermatosis. In many cases, PG is associated with a wide variety of different disorders but SLE in association with PG is relatively uncommon. In this article we present the case of a middle aged patient with PG as the initial clinical presentation of SLE. We also provide a brief review of cobalamin deficiency which occurred in our patient and evidence-based management options. Case presentation: A 35 years old man presented with a 5 month history of debilitating painful lower limb and scrotal ulcers. This was associated with polyarthralgia and morning stiffness involving both hands. He also complained of swallowing difficulties. He had unintentional weight loss of 10 kg and fatigue. Physical examination revealed alopecia, multiple cervical lymphadenopathies, bilateral parotid gland enlargement and atrophic glossitis. There was Raynaud’s phenomenon noted over both hands and generalised hyper-pigmented fragile skin. Laboratory results disclosed anaemia, leukopenia, hyponatraemia and hypocortisolism. Detailed anaemic workup revealed low serum ferritin and cobalamin level. The autoimmune screen showed positive ANA, anti SmD1, anti SS- A/Ro 52, anti SSA/Ro 60, anti U1-snRNP with low complement levels. Upper gastrointestinal endoscopy with biopsies confirmed atrophic gastritis and duodenitis. Intrinsic factor antibodies and anti-tissue transglutaminase IgA were all negative.
    [Show full text]
  • Sarcoidosis and Pyoderma Gangrenosum, an Unusual
    Open Journal of Clinical & Medical Volume 4 (2018) Issue 19 Case Reports ISSN 2379-1039 Sarcoidosis and pyoderma gangrenosum, an unusual combination Naval Mendiratta*; Muzafar Bindroo Ahmed; Shruti Bajad; Rajiva Gupta *Naval Mendiratta Department of Rheumatology and Clinical Immunology, Medanta Hospital Gurgaon, Haryana, India Email: [email protected] Abstract We present a case of unusual combination of Sarcoidosis with refractory Pyoderma Gangrenosum. Pyoderma Gangrenosum has been a reported with other autoimmune disorders like Rheumatoid Arthritis and Ulcerative colitis but it has hardly ever been reported with another rare disease like Sarcoidosis. Here we present a case of 39 year old female, who was diagnosed and treated for Sarcoidosis but later presented to our OPD with worsening skin lesions which were biopsied and diagnosed as Pyoderma Gangrenosum. Not only were they unusual, but they were even refractory to standard medical therapy. Keywords pyoderma; sarcoidosis; refractory pyoderma; cyclophosphamide Abbreviations ESR : Erythrocyte sedimentation rat; CRP: C- Reactive protein; CT: Computerized tomography; EUS: Endoscopic ultrasound; FNAC: Fine needle aspiration cytology; AFB: Acid fast bacilli; OPD: Out patient department; ACE : Angiotensin converting enzyme Case Report 39 year old female, was referred to our OPD for further management once the diagnosis of Sarcoidosis was conirmed. Symptoms started in December 2014, when she had complaints of fever along with cough. Further evaluation was done and a chest CT revealed multiple mediastinal lymph nodes. Patient was started on empiricalanti tubercular drugs (4 drug regimen ) ,which was given for 6 months. She felt better during the treatment course but after a period of 2 months, she started having again low grade fever with myalgia's and arthalgias.
    [Show full text]
  • Pyoderma Gangrenosum with Positive Antinuclear Antibody, in the Absence of Systemic Association
    Case Report http://dx.doi.org/10.3126/njdvl.v16i1.19418 Pyoderma Gangrenosum with Positive Antinuclear Antibody, in the Absence of Systemic Association Shrestha S1, Aryal A2 1Lecturer, 2Second Year Resident, Department of Dermatology, Dhulikhel Hospital, Kathmandu University-Teaching Hospital, Dhulikhel, Kavre, Nepal. Abstract Pyoderma gangrenosum is an uncommon neutrophilic dermatosis, seen on legs, and infrequently on hands and other anatomical sites. It is associated with systemic diseases in 50-70% of the cases. Antinuclear antibody (ANA) seropositivity has been reported in pyoderma gangrenosum associated with connective tissue disorders. However, there are very few case reports of pyoderma gangrenosum in patients of systemic lupus erythematosus, while we did not find any reports of ANA seropositivity in isolated pyoderma gangrenosum. Hence, we report this unique case of pyoderma gangrenosum with classical clinicohistopathology, positive ANA but no systemic association. As anticipated, our patient responded promptly to steroids. Key words: Antibodies; connective tissue diseases; lupus erythematosus; vasculitis, leukocytoclastic Introduction systemic comorbidi es were elicited from history. She was a nonsmoker. yoderma gangrenosum (PG) is a rare necro zing, Pulcera ve neutrophilic dermatosis.1 It is usually On examina on, pa ent was afebrile with normal associated with various systemic illnesses, but vital signs (BP 100/60 mm of mercury, Pulse 84/m, rarely described in associa on with systemic lupus RR 18/min). Cutaneous examina on revealed fi ve erythematosus (SLE) or an nuclear an body (ANA) annular lesions on sun-exposed sites of hands and seroposi vity. We report this case of PG on sunexposed feet (Figure 1). Among them, only one lesion on right sites, with posi ve ANA and no internal disease.
    [Show full text]
  • The Inpatient Burden and Comorbidities of Pyoderma Gangrenosum in Adults in the United States
    Henry Ford Health System Henry Ford Health System Scholarly Commons Dermatology Articles Dermatology 7-3-2020 The inpatient burden and comorbidities of pyoderma gangrenosum in adults in the United States Shanthi Narla Henry Ford Health System, [email protected] Jonathan I. Silverberg Follow this and additional works at: https://scholarlycommons.henryford.com/dermatology_articles Recommended Citation Narla S, and Silverberg JI. The inpatient burden and comorbidities of pyoderma gangrenosum in adults in the United States. Arch Dermatol Res 2020. This Article is brought to you for free and open access by the Dermatology at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Dermatology Articles by an authorized administrator of Henry Ford Health System Scholarly Commons. Archives of Dermatological Research https://doi.org/10.1007/s00403-020-02098-7 ORIGINAL PAPER The inpatient burden and comorbidities of pyoderma gangrenosum in adults in the United States Shanthi Narla1 · Jonathan I. Silverberg2 Received: 24 April 2020 / Accepted: 17 June 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020 Abstract Hospital admission is often necessary for management of pyoderma gangrenosum (PG), including wound care and pain con- trol. No large-scale controlled studies examined the burden of hospitalization for PG. The objective of this study is to deter- mine the prevalence, predictors, outcomes, and costs of hospitalization for PG in United States adults. Data were analyzed from the 2002 to 2012 National Inpatient Sample, including a 20% representative sample of United States hospitalizations. The prevalence of hospitalization for PG increased between 2002 and 2012. Primary admission for PG was associated with age 40–59 years, female sex, black race/ethnicity, second-quartile household income, public or no insurance, and multiple chronic conditions.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Skin and Soft Tissue Infections Ohsuerin Bonura, MD, MCR Oregon Health & Science University Objectives
    Difficult Skin and Soft tissue Infections OHSUErin Bonura, MD, MCR Oregon Health & Science University Objectives • Compare and contrast the epidemiology and clinical presentation of common skin and soft tissue diseases • State the management for skin and soft tissue infections OHSU• Differentiate true infection from infectious disease mimics of the skin Casey Casey is a 2 year old boy who presents with this rash. What is the best treatment? A. Soap and Water B. Ibuprofen, it will self OHSUresolve C. Dicloxacillin D. Mupirocin OHSUImpetigo Impetigo Epidemiology and Treatment OHSU Ellen Ellen is a 54 year old morbidly obese woman with DM, HTN and venous stasis who presented with a painful left leg and fever. She has had 3 episodes in the last 6 months. What do you recommend? A. Cefazolin followed by oral amoxicillin prophylaxis B. Vancomycin – this is likely OHSUMRSA C. Amoxicillin – this is likely erysipelas D. Clindamycin to cover staph and strep cellulitis Impetigo OHSUErysipelas Erysipelas Risk: lymphedema, stasis, obesity, paresis, DM, ETOH OHSURecurrence rate: 30% in 3 yrs Treatment: Penicillin Impetigo Erysipelas OHSUCellulitis Cellulitis • DEEPER than erysipelas • Microbiology: – 6-48hrs post op: think GAS… too early for staph (days in the making)! – Periorbital – Staph, Strep pneumoniae, GAS OHSU– Post Varicella - GAS – Skin popping – Staph + almost anything! Framework for Skin and Soft Tissue Infections (SSTIs) NONPurulent Purulent Necrotizing/Cellulitis/Erysipelas Furuncle/Carbuncle/Abscess Severe Moderate Mild Severe Moderate Mild I&D I&D I&D I&D IV Rx Oral Rx C&S C&S C&S C&S Vanc + Pip-tazo OHSUEmpiric IV Empiric MRSA Oral MRSA TMP/SMX Doxy What Are Your “Go-To” Oral Options For Non-Purulent SSTI? Amoxicillin Doxycycline OHSUCephalexin Doxycycline Trimethoprim-Sulfamethoxazole OHSU Miller LG, et al.
    [Show full text]
  • Pyoderma Gangrenosum: Challenges and Solutions
    Clinical, Cosmetic and Investigational Dermatology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Pyoderma gangrenosum: challenges and solutions Ana Gameiro1 Abstract: Pyoderma gangrenosum (PG) is a rare disease, but commonly related to important Neide Pereira2 morbidity. PG was first assumed to be infectious, but is now considered an inflammatory neutro- José Carlos Cardoso1 philic disease, often associated with autoimmunity, and with chronic inflammatory and neoplastic Margarida Gonçalo1 diseases. Currently, many aspects of the underlying pathophysiology are not well understood, and etiology still remains unknown. PG presents as painful, single or multiple lesions, with several 1Dermatology Department, Coimbra University Hospital, Coimbra, clinical variants, in different locations, with a non specific histology, which makes the diagnosis Portugal; 2Dermatology Department, challenging and often delayed. In the classic ulcerative variant, characterized by ulcers with Centro Hospitalar Cova da Beira, inflammatory undermined borders, a broad differential diagnosis of malignancy, infection, and Covilhã, Portugal vasculitis needs to be considered, making PG a diagnosis of exclusion. Moreover, there are no For personal use only. definitively accepted diagnostic criteria. Treatment is also challenging since, due to its rarity, clinical trials are difficult to perform, and consequently, there is no “gold standard” therapy. Patients frequently require aggressive immunosuppression, often in multidrug
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Pyoderma Gangrenosum in Myelodysplasia and Acute Leukaemia
    Postgrad Med J: first published as 10.1136/pgmj.61.718.689 on 1 August 1985. Downloaded from Postgraduate Medical Journal (1985) 61, 689-694 Pyoderma gangrenosum in myelodysplasia and acute leukaemia Peter Jacobs', S. Palmer2 and E.C. Gordon-Smith2 'The University ofCape Town Leukaemia Centre and the Department ofHaematology, Groote Schuur Hospital, Observatory, 7925, Cape Town, South Africa and 'The Department ofHaematology, Royal Postgraduate Medical School, London, UK. Summary: Pyoderma gangrenosum is a rare occurrence in patients with haematological malignancy. This characteristic but nonspecific inflammatory process with skin destruction occurred in 4 patients with myelodysplasia, in one with acute leukaemic transformation of myelofibrosis, and in de novo acute myeloblastic leukaemia in another. Clinically, the cutaneous lesion in these patients differed from that associated with inflammatory bowel disease, arthritis, or the idiopathic type ofpyoderma gangrenosum by having the vesiculo-bulious borders. Histopathological differences were also evident since more superficial layers ofthe skin were involved in the ulceration than typically encountered in patients with non-malignant systemic disease. Despite the less penetrating nature of this variant, treatment of the pyoderma gangrenosum is unsatisfactory and in the absence of effective therapy for the underlying disease, healing occurred only in the patient with acute leukaemia who achieved complete remission in response to chemotherapy. copyright. Introduction Pyoderma gangrenosum
    [Show full text]
  • Module Test № 1 on Dermatology
    THE MINISTRY OF HEALTHCARE OF THE RUSSIAN FEDERATION FEDERAL STATE BUDGETARY EDUCATIONAL INSTITUTION OF HIGHER PROFESSIONAL EDUCATION PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY DEPARTMENT OF DERMATOVENEROLOGY Gaydina T.A., Dvornikov A.S., Skripkina P.A., Nazhmutdinova D.K., Heydar S.A., Arutunyan G.B., Pashinyan A.G. MODULE TEST №1 ON DERMATOLOGY FOR STUDENTS OF INSTITUTES OF HIGHER MEDICAL EDUCATION ON SPECIALTY THERAPEUTIC FACULTY DEPARTMENT OF DERMATOVENEROLOGY Moscow 2016 ISBN УДК ББК A21 Module test №1 on Dermatology for students of institutes of high medical education on specialty «Therapeutic faculty» department of dermatovenerology: manual for students for self-training//FSBEI HPE “Pirogov RNRMU” of the ministry of healthcare of the russian federation, M.: (publisher) 2016, 144 p. The manual is a part of teaching-methods on Dermatovenerology. It contains tests on Dermatology on the topics of practical sessions requiring single or multiple choice anser. The manual can be used to develop skills of students during practical sessions. It also can be used in the electronic version at testing for knowledge. The manual is compiled according to FSES on specialty “therapeutic faculty”, working programs on dermatovenerology. The manual is intended for foreign students of 3-4 courses on specialty “therapeutic faculty” and physicians for professional retraining. Authors: Gaydina T.A. – candidate of medical science, assistant of dermatovenerology department of therapeutic faculty Pirogov RNRMU Dvornikov A.S. – M.D., professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Skripkina P.A. – candidate of medical science, assistant professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Nazhmutdinova D.K. – candidate of medical science, assistant professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Heydar S.A.
    [Show full text]
  • Morphology of HS and AC Overlap Making a True Taxonomic Distinction Between Them Difficult (Figure 31, Figure 32)
    Volume 20 Number 4 April 2014 Review An atlas of the morphological manifestations of hidradenitis suppurativa Noah Scheinfeld Dermatology Online Journal 20 (4): 4 Weil Cornell Medical College Correspondence: Noah Scheinfeld MD JD Assistant Clinical Professor of Dermatology Weil Cornell Medical College 150 West 55th Street NYC NY [email protected] Abstract This article is dermatological atlas of the morphologic presentations of Hidradenitis Suppurativa (HS). It includes: superficial abscesses (boils, furnucles, carbuncles), abscesses that are subcutaneous and suprafascial, pyogenic granulomas, cysts, painful erythematous papules and plaques, folliculitis, open ulcerations, chronic sinuses, fistulas, sinus tracts, scrotal and genital lyphedema, dermal contractures, keloids (some that are still pitted with follicular ostia), scarring, skin tags, fibrosis, anal fissures, fistulas (i.e. circinate, linear, arcuate), scarring folliculitis of the buttocks (from mild to cigarette-like scarring), condyloma like lesions in intertrigous areas, fishmouth scars, acne inversa, honey-comb scarring, cribiform scarring, tombstone comedones, and morphia-like plaques. HS can co-exist with other follicular diseases such as pilonidal cysts, dissecting cellulitis, acne conglobata, pyoderma gangrenosum, and acanthosis nigricans. In sum, the variety of presentations of HS as shown by these images supports the supposition that HS is a reaction pattern. HS is a follicular based diseased and its manifestations involve a multitude of follicular pathologies [1,2]. It is also known as acne inversa (AI) because of one manifestation that involves the formation of open comedones on areas besides the face. It is as yet unclear why HS is so protean in its manifestations. HS severity is assessed using the Hurley Staging System (Table 1).
    [Show full text]
  • Superficial Pyoderma
    W2825-Ch003.qxd 8/4/2005 13:33 Page 34 34 CHAPTER 3 Bacterial Skin Diseases Superficial Pyoderma (superficial bacterial folliculitis) Features emerging as a common canine isolate in patients with Superficial pyoderma is a superficial bacterial infection chronic infections and previous antibiotic exposure. Ad- involving hair follicles and the adjacent epidermis. The ditionally, methicillin-resistant Staphylococcus aureus infection usually occurs secondary to an underlying (human MRSA) may be becoming more common cause; allergies and endocrine disease are the most among veterinary species. common causes (Box 3-3). Superficial pyoderma is common in dogs and rare in cats. Superficial pyoderma is characterized by focal, mul- Top Differentials tifocal, or generalized areas of papules, pustules, Differentials include demodicosis, dermatophytosis, crusts, and scales, epidermal collarettes, or circum- scabies, and autoimmume skin diseases. scribed areas of erythema and alopecia that may have hyperpigmented centers. Short-coated dogs often present with a “moth-eaten” patchy alopecia, small Diagnosis tufts of hair that stand up, or reddish brown discol- 1. Rule out other differentials oration of white hairs. In long-coated dogs, symptoms 2. Cytology (pustule): neutrophils and bacterial cocci can be insidious and may include a dull, lusterless hair 3. Dermatohistopathology: epidermal microabscesses, coat, scales, and excessive shedding. In both short- and nonspecific superficial dermatitis, perifolliculitis, long-coated breeds, primary skin lesions are often and folliculitis. Intralesional bacteria may be diffi- obscured by remaining hairs but can be readily appre- cult to find ciated if an affected area is clipped. Pruritus is variable, 4. Bacterial culture: Staphylococcus species ranging from none to intense levels.
    [Show full text]